Onkologie. 2024:18(Suppl.C):25-30 | DOI: 10.36290/xon.2024.047

Enfortumab vedotin in the treatment of urothelial bladder carcinoma

Kateřina Pejřová, Anežka Zemánková
Onkologická klinika, Fakultní nemocnice Olomouc

The case report describes the case of a 67-year-old woman with metastatic urothelial carcinoma. For the first-line chemotherapy carboplatin/gemcitabine regimen was chosen. Due to a partial response, the maintenance treatment with avelumab was subsequently continued, but the disease relapsed after 3 months of the therapy. According to the current standard of treatment of urothelial bladder carcinoma, the patient started the second-line treatment with enfortumab vedotin. A partial response was achieved after 3 months of the therapy with enfortumab vedotin and the patient benefited from the treatment for a total of 8 months.

Keywords: bladder carcinoma, enfortumab vedotin, partial response.

Accepted: September 12, 2024; Published: October 2, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pejřová K, Zemánková A. Enfortumab vedotin in the treatment of urothelial bladder carcinoma. Onkologie. 2024;18(Suppl.C):25-30. doi: 10.36290/xon.2024.047.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Büchler T. Speciální onkologie. 2. vydání. Jessenius. Praha: Maxdorf; 2020.
    2. Šlampa P a kol. Radiační onkologie: pro postgraduální přípravu i každodenní praxi. Jessenius. Praha: Maxdorf; 2021.
    3. Zhoubný novotvar močového měchýře. [Internet]. Linkos. © 2024. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/asd-22-zhoubny-novotvar-mocoveho-mechyre-c67/. [cit. 2024-07-28].
    4. SPC - Padcev, INN-enfortumab vedotin. [Internet]. 2023; p. 40. Available from: https://www.ema.europa.eu/en/documents/product-information/padcev-epar-product-information_en.pdf. [cit. 2024-08-02].
    5. Enfortumab vedotin. [Internet]. Linkos. © 2024. Available from: https://www.linkos.cz/slovnicek/enfortumab-vedotin-ucinna-latka/. [cit. 2024-08-02].
    6. Miletín M. Konjugované monoklonální protilátky. Klin farmakol farm. 2018;32(4):32-37. Available from: https://www.klinickafarmakologie.cz/pdfs/far/2018/04/05.pdf. [cit. 2024-08-02]. Go to original source...
    7. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021;384(12):1125-1135. Go to original source... Go to PubMed...
    8. Powles T, Valderr BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(6):875-888. Go to original source... Go to PubMed...
    9. Avelumab. [Internet]. Linkos. © 2024. Available from: https://www.linkos.cz/slovnicek/avelumab-ucinna-latka/. [cit. 2024-07-28].

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.